microbes-infection-2017-keynote

2 / 7

alliedacademies
Page 10
Microbiology: Current Research 2017
Volume 1 Issue 2
Notes:
Microbes Infection 2017
September 28-29, 2017 | London, UK
Microbes Infection
38th Annual congress on
Sanjib Bhakta, Microbiology: Current Research 2017
Repurposing common non-steroidal anti
inflammatory drugs (NSAIDs) could potentially
reverse intrinsic antimicrobial resistance in TB
Aims: Non-steroidal anti-inflammatory drugs (NSAIDs),
successfully used against a range of human and animal
illnesses, were reported to display antibiotic action against
replicating, non-replicating and multi-drug-resistant clinical
isolates of the tuberculosis (TB)-causing dreadful bacterial
pathogen Mycobacterium tuberculosis . In this project, we
have extended our investigation on NSAIDs anti-tubercular
specific endogenous mode(s) and mechanism(s) of action.
Results: Interdisciplinary research methods were used to
achieve the objectives of this project. The most potent NSAID
so far, at sub-inhibitory concentrations, inhibited whole-cell
efflux pumps activity at par with/better than potent efflux
pump inhibitors such as verapamil and chlorpromazine.
In addition, the NSAID inhibited mycobacterial biofilm
formation significantly. Analysis of the extracellular polymeric
substances of treated biofilm showed macromolecular
alterations compared to the untreated controls. Furthermore,
transcriptomic analysis revealed modulation of key metabolic
pathways in NSAID-treated M. tuberculosis revealing novel
endogenous targets of the drug.
Conclusions: NSAIDs have the potential to reverse
antimicrobial resistance by inhibiting efflux pumps and
biofilm formation.
Significance: The exponential increase of antimicrobial
resistance in TB has led to an insurmountable economic
and scientific challenge worldwide. Drug repurposing offers
a direct route to phase III clinical trials, thereby reducing
the investment of time and finances. The over-the-counter
immunomodulatory drug’s new antibiotic action has paved an
alternative route for tackling antimicrobial resistance in TB.
Biography
Sanjib Bhakta is a world-leading TB-expert and Academic Head of the ISMB-
Mycobacteria Research Laboratory at the Institute of Structural and Molecular Biology.
His continued research interest in global infectious diseases (funded by Wellcome Trust,
Research Council-UK, EU and International Newton Fund) is focused on developing
novel therapeutics as well as repurposing existing drugs to tackle antimicrobial
resistance and persistence in TB. He has published around 100 original research
articles for a number of internationally acclaimed journals viz. J. Exp. Med., J. Biol.
Chem., Tuberculosis, Biochemical Journal, Journal of Antimicrobial Chemotherapy,
FEBS J, Molecular Microbiology, British Medical Journal, British Medical Bulletin, PLOS
and Journal of Medicinal Chemistry. As a UK-STEM Ambassador and BSAC-Antibiotic
Action Champion, he has volunteered on the Wellcome Trust/Research Council-UK
funded program “Researchers in Residence” at local schools in London and has
contributed to British Museum science program “News & Views”.
Sanjib Bhakta
University of London, UK